Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
161,353
archived clinical trials in
Cancer

Multivalent HPV (Human Papillomavirus) Vaccine Study in 16- to 26-Year Old Men and Women (V503-003 AM5)
A Phase III Clinical Trial to Study the Tolerability and Immunogenicity of V503, a Multivalent Human Papillomavirus (HPV) L1 Virus-Like Particle (VLP) Vaccine, in 16- to 26-Year-Old Men and 16- to 26-Year-Old Women
Status: Enrolling
Updated:  6/26/2013
Clinical Research Facility
mi
from
New York, NY
Multivalent HPV (Human Papillomavirus) Vaccine Study in 16- to 26-Year Old Men and Women (V503-003 AM5)
A Phase III Clinical Trial to Study the Tolerability and Immunogenicity of V503, a Multivalent Human Papillomavirus (HPV) L1 Virus-Like Particle (VLP) Vaccine, in 16- to 26-Year-Old Men and 16- to 26-Year-Old Women
Status: Enrolling
Updated: 6/26/2013
Clinical Research Facility
mi
from
New York, NY
Click here to add this to my saved trials
Multivalent HPV (Human Papillomavirus) Vaccine Study in 16- to 26-Year Old Men and Women (V503-003 AM5)
A Phase III Clinical Trial to Study the Tolerability and Immunogenicity of V503, a Multivalent Human Papillomavirus (HPV) L1 Virus-Like Particle (VLP) Vaccine, in 16- to 26-Year-Old Men and 16- to 26-Year-Old Women
Status: Enrolling
Updated:  6/26/2013
Clinical Research Facility
mi
from
Rochester, NY
Multivalent HPV (Human Papillomavirus) Vaccine Study in 16- to 26-Year Old Men and Women (V503-003 AM5)
A Phase III Clinical Trial to Study the Tolerability and Immunogenicity of V503, a Multivalent Human Papillomavirus (HPV) L1 Virus-Like Particle (VLP) Vaccine, in 16- to 26-Year-Old Men and 16- to 26-Year-Old Women
Status: Enrolling
Updated: 6/26/2013
Clinical Research Facility
mi
from
Rochester, NY
Click here to add this to my saved trials
Multivalent HPV (Human Papillomavirus) Vaccine Study in 16- to 26-Year Old Men and Women (V503-003 AM5)
A Phase III Clinical Trial to Study the Tolerability and Immunogenicity of V503, a Multivalent Human Papillomavirus (HPV) L1 Virus-Like Particle (VLP) Vaccine, in 16- to 26-Year-Old Men and 16- to 26-Year-Old Women
Status: Enrolling
Updated:  6/26/2013
Clinical Research Facility
mi
from
Cincinnati, OH
Multivalent HPV (Human Papillomavirus) Vaccine Study in 16- to 26-Year Old Men and Women (V503-003 AM5)
A Phase III Clinical Trial to Study the Tolerability and Immunogenicity of V503, a Multivalent Human Papillomavirus (HPV) L1 Virus-Like Particle (VLP) Vaccine, in 16- to 26-Year-Old Men and 16- to 26-Year-Old Women
Status: Enrolling
Updated: 6/26/2013
Clinical Research Facility
mi
from
Cincinnati, OH
Click here to add this to my saved trials
Multivalent HPV (Human Papillomavirus) Vaccine Study in 16- to 26-Year Old Men and Women (V503-003 AM5)
A Phase III Clinical Trial to Study the Tolerability and Immunogenicity of V503, a Multivalent Human Papillomavirus (HPV) L1 Virus-Like Particle (VLP) Vaccine, in 16- to 26-Year-Old Men and 16- to 26-Year-Old Women
Status: Enrolling
Updated:  6/26/2013
Clinical Research Facility
mi
from
Levittown, PA
Multivalent HPV (Human Papillomavirus) Vaccine Study in 16- to 26-Year Old Men and Women (V503-003 AM5)
A Phase III Clinical Trial to Study the Tolerability and Immunogenicity of V503, a Multivalent Human Papillomavirus (HPV) L1 Virus-Like Particle (VLP) Vaccine, in 16- to 26-Year-Old Men and 16- to 26-Year-Old Women
Status: Enrolling
Updated: 6/26/2013
Clinical Research Facility
mi
from
Levittown, PA
Click here to add this to my saved trials
Multivalent HPV (Human Papillomavirus) Vaccine Study in 16- to 26-Year Old Men and Women (V503-003 AM5)
A Phase III Clinical Trial to Study the Tolerability and Immunogenicity of V503, a Multivalent Human Papillomavirus (HPV) L1 Virus-Like Particle (VLP) Vaccine, in 16- to 26-Year-Old Men and 16- to 26-Year-Old Women
Status: Enrolling
Updated:  6/26/2013
Clinical Research Facility
mi
from
Philadelphia, PA
Multivalent HPV (Human Papillomavirus) Vaccine Study in 16- to 26-Year Old Men and Women (V503-003 AM5)
A Phase III Clinical Trial to Study the Tolerability and Immunogenicity of V503, a Multivalent Human Papillomavirus (HPV) L1 Virus-Like Particle (VLP) Vaccine, in 16- to 26-Year-Old Men and 16- to 26-Year-Old Women
Status: Enrolling
Updated: 6/26/2013
Clinical Research Facility
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Multivalent HPV (Human Papillomavirus) Vaccine Study in 16- to 26-Year Old Men and Women (V503-003 AM5)
A Phase III Clinical Trial to Study the Tolerability and Immunogenicity of V503, a Multivalent Human Papillomavirus (HPV) L1 Virus-Like Particle (VLP) Vaccine, in 16- to 26-Year-Old Men and 16- to 26-Year-Old Women
Status: Enrolling
Updated:  6/26/2013
Clinical Research Facility
mi
from
Providence, RI
Multivalent HPV (Human Papillomavirus) Vaccine Study in 16- to 26-Year Old Men and Women (V503-003 AM5)
A Phase III Clinical Trial to Study the Tolerability and Immunogenicity of V503, a Multivalent Human Papillomavirus (HPV) L1 Virus-Like Particle (VLP) Vaccine, in 16- to 26-Year-Old Men and 16- to 26-Year-Old Women
Status: Enrolling
Updated: 6/26/2013
Clinical Research Facility
mi
from
Providence, RI
Click here to add this to my saved trials
Multivalent HPV (Human Papillomavirus) Vaccine Study in 16- to 26-Year Old Men and Women (V503-003 AM5)
A Phase III Clinical Trial to Study the Tolerability and Immunogenicity of V503, a Multivalent Human Papillomavirus (HPV) L1 Virus-Like Particle (VLP) Vaccine, in 16- to 26-Year-Old Men and 16- to 26-Year-Old Women
Status: Enrolling
Updated:  6/26/2013
Clinical Research Facility
mi
from
Nashville, TN
Multivalent HPV (Human Papillomavirus) Vaccine Study in 16- to 26-Year Old Men and Women (V503-003 AM5)
A Phase III Clinical Trial to Study the Tolerability and Immunogenicity of V503, a Multivalent Human Papillomavirus (HPV) L1 Virus-Like Particle (VLP) Vaccine, in 16- to 26-Year-Old Men and 16- to 26-Year-Old Women
Status: Enrolling
Updated: 6/26/2013
Clinical Research Facility
mi
from
Nashville, TN
Click here to add this to my saved trials
Multivalent HPV (Human Papillomavirus) Vaccine Study in 16- to 26-Year Old Men and Women (V503-003 AM5)
A Phase III Clinical Trial to Study the Tolerability and Immunogenicity of V503, a Multivalent Human Papillomavirus (HPV) L1 Virus-Like Particle (VLP) Vaccine, in 16- to 26-Year-Old Men and 16- to 26-Year-Old Women
Status: Enrolling
Updated:  6/26/2013
Clinical Research Facility
mi
from
Houston, TX
Multivalent HPV (Human Papillomavirus) Vaccine Study in 16- to 26-Year Old Men and Women (V503-003 AM5)
A Phase III Clinical Trial to Study the Tolerability and Immunogenicity of V503, a Multivalent Human Papillomavirus (HPV) L1 Virus-Like Particle (VLP) Vaccine, in 16- to 26-Year-Old Men and 16- to 26-Year-Old Women
Status: Enrolling
Updated: 6/26/2013
Clinical Research Facility
mi
from
Houston, TX
Click here to add this to my saved trials
Multivalent HPV (Human Papillomavirus) Vaccine Study in 16- to 26-Year Old Men and Women (V503-003 AM5)
A Phase III Clinical Trial to Study the Tolerability and Immunogenicity of V503, a Multivalent Human Papillomavirus (HPV) L1 Virus-Like Particle (VLP) Vaccine, in 16- to 26-Year-Old Men and 16- to 26-Year-Old Women
Status: Enrolling
Updated:  6/26/2013
Clinical Research Facility
mi
from
Salt Lake City, UT
Multivalent HPV (Human Papillomavirus) Vaccine Study in 16- to 26-Year Old Men and Women (V503-003 AM5)
A Phase III Clinical Trial to Study the Tolerability and Immunogenicity of V503, a Multivalent Human Papillomavirus (HPV) L1 Virus-Like Particle (VLP) Vaccine, in 16- to 26-Year-Old Men and 16- to 26-Year-Old Women
Status: Enrolling
Updated: 6/26/2013
Clinical Research Facility
mi
from
Salt Lake City, UT
Click here to add this to my saved trials
Multivalent HPV (Human Papillomavirus) Vaccine Study in 16- to 26-Year Old Men and Women (V503-003 AM5)
A Phase III Clinical Trial to Study the Tolerability and Immunogenicity of V503, a Multivalent Human Papillomavirus (HPV) L1 Virus-Like Particle (VLP) Vaccine, in 16- to 26-Year-Old Men and 16- to 26-Year-Old Women
Status: Enrolling
Updated:  6/26/2013
Clinical Research Facility
mi
from
Richmond, VA
Multivalent HPV (Human Papillomavirus) Vaccine Study in 16- to 26-Year Old Men and Women (V503-003 AM5)
A Phase III Clinical Trial to Study the Tolerability and Immunogenicity of V503, a Multivalent Human Papillomavirus (HPV) L1 Virus-Like Particle (VLP) Vaccine, in 16- to 26-Year-Old Men and 16- to 26-Year-Old Women
Status: Enrolling
Updated: 6/26/2013
Clinical Research Facility
mi
from
Richmond, VA
Click here to add this to my saved trials
Therapy of HES, PV, Atypical CML or CMML, and Mastocytosis With Imatinib Mesylate
Therapy of Hypereosinophilic Syndrome, Polycythemia Vera, Atypical CML or CMML With PDGF-R Fusion Genes, or Mastocytosis With Imatinib Mesylate (STI571)
Status: Enrolling
Updated:  6/26/2013
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Therapy of HES, PV, Atypical CML or CMML, and Mastocytosis With Imatinib Mesylate
Therapy of Hypereosinophilic Syndrome, Polycythemia Vera, Atypical CML or CMML With PDGF-R Fusion Genes, or Mastocytosis With Imatinib Mesylate (STI571)
Status: Enrolling
Updated: 6/26/2013
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Click here to add this to my saved trials
A Dose Escalation Study of MK1775 in Combination With Either Gemcitabine, Cisplatin, or Carboplatin in Adults With Advanced Solid Tumors (MK-1775-001 AM7)
A Phase I Dose Escalation Study Evaluating MK1775 in Both Monotherapy and in Combination With Either Gemcitabine, Cisplatin, or Carboplatin in Adult Subjects With Advanced Solid Tumors
Status: Enrolling
Updated:  6/27/2013
Clinical Research Facility
mi
from
San Francisco, CA
A Dose Escalation Study of MK1775 in Combination With Either Gemcitabine, Cisplatin, or Carboplatin in Adults With Advanced Solid Tumors (MK-1775-001 AM7)
A Phase I Dose Escalation Study Evaluating MK1775 in Both Monotherapy and in Combination With Either Gemcitabine, Cisplatin, or Carboplatin in Adult Subjects With Advanced Solid Tumors
Status: Enrolling
Updated: 6/27/2013
Clinical Research Facility
mi
from
San Francisco, CA
Click here to add this to my saved trials
A Dose Escalation Study of MK1775 in Combination With Either Gemcitabine, Cisplatin, or Carboplatin in Adults With Advanced Solid Tumors (MK-1775-001 AM7)
A Phase I Dose Escalation Study Evaluating MK1775 in Both Monotherapy and in Combination With Either Gemcitabine, Cisplatin, or Carboplatin in Adult Subjects With Advanced Solid Tumors
Status: Enrolling
Updated:  6/27/2013
Clinical Research Facility
mi
from
Waltham, MA
A Dose Escalation Study of MK1775 in Combination With Either Gemcitabine, Cisplatin, or Carboplatin in Adults With Advanced Solid Tumors (MK-1775-001 AM7)
A Phase I Dose Escalation Study Evaluating MK1775 in Both Monotherapy and in Combination With Either Gemcitabine, Cisplatin, or Carboplatin in Adult Subjects With Advanced Solid Tumors
Status: Enrolling
Updated: 6/27/2013
Clinical Research Facility
mi
from
Waltham, MA
Click here to add this to my saved trials
Capecitabine and Temozolomide for Neuroendocrine Cancers
Phase II Study of Capecitabine and Temozolomide for Progressive, Differentiated, Metastatic Neuroendocrine Cancers
Status: Enrolling
Updated:  7/1/2013
Columbia University Medical Center
mi
from
New York, NY
Capecitabine and Temozolomide for Neuroendocrine Cancers
Phase II Study of Capecitabine and Temozolomide for Progressive, Differentiated, Metastatic Neuroendocrine Cancers
Status: Enrolling
Updated: 7/1/2013
Columbia University Medical Center
mi
from
New York, NY
Click here to add this to my saved trials
FOLFOXIRI Plus Panitumumab Patients With Metastatic KRAS Wild-Type Colorectal Cancer With Liver Metastases Only
A Phase II Study of FOLFOXIRI Plus Panitumumab Followed by Evaluation for Resection, in Patients With Metastatic KRAS Wild-Type Colorectal Cancer With Liver Metastases Only
Status: Enrolling
Updated:  7/1/2013
NEA Baptist Clinic
mi
from
Jonesboro, AR
FOLFOXIRI Plus Panitumumab Patients With Metastatic KRAS Wild-Type Colorectal Cancer With Liver Metastases Only
A Phase II Study of FOLFOXIRI Plus Panitumumab Followed by Evaluation for Resection, in Patients With Metastatic KRAS Wild-Type Colorectal Cancer With Liver Metastases Only
Status: Enrolling
Updated: 7/1/2013
NEA Baptist Clinic
mi
from
Jonesboro, AR
Click here to add this to my saved trials
FOLFOXIRI Plus Panitumumab Patients With Metastatic KRAS Wild-Type Colorectal Cancer With Liver Metastases Only
A Phase II Study of FOLFOXIRI Plus Panitumumab Followed by Evaluation for Resection, in Patients With Metastatic KRAS Wild-Type Colorectal Cancer With Liver Metastases Only
Status: Enrolling
Updated:  7/1/2013
Florida Cancer Specialists
mi
from
Fort Myers, FL
FOLFOXIRI Plus Panitumumab Patients With Metastatic KRAS Wild-Type Colorectal Cancer With Liver Metastases Only
A Phase II Study of FOLFOXIRI Plus Panitumumab Followed by Evaluation for Resection, in Patients With Metastatic KRAS Wild-Type Colorectal Cancer With Liver Metastases Only
Status: Enrolling
Updated: 7/1/2013
Florida Cancer Specialists
mi
from
Fort Myers, FL
Click here to add this to my saved trials
FOLFOXIRI Plus Panitumumab Patients With Metastatic KRAS Wild-Type Colorectal Cancer With Liver Metastases Only
A Phase II Study of FOLFOXIRI Plus Panitumumab Followed by Evaluation for Resection, in Patients With Metastatic KRAS Wild-Type Colorectal Cancer With Liver Metastases Only
Status: Enrolling
Updated:  7/1/2013
Northeast Georgia Medical Center
mi
from
Gainesville, GA
FOLFOXIRI Plus Panitumumab Patients With Metastatic KRAS Wild-Type Colorectal Cancer With Liver Metastases Only
A Phase II Study of FOLFOXIRI Plus Panitumumab Followed by Evaluation for Resection, in Patients With Metastatic KRAS Wild-Type Colorectal Cancer With Liver Metastases Only
Status: Enrolling
Updated: 7/1/2013
Northeast Georgia Medical Center
mi
from
Gainesville, GA
Click here to add this to my saved trials
FOLFOXIRI Plus Panitumumab Patients With Metastatic KRAS Wild-Type Colorectal Cancer With Liver Metastases Only
A Phase II Study of FOLFOXIRI Plus Panitumumab Followed by Evaluation for Resection, in Patients With Metastatic KRAS Wild-Type Colorectal Cancer With Liver Metastases Only
Status: Enrolling
Updated:  7/1/2013
Providence Medical Group
mi
from
Terre Haute, IN
FOLFOXIRI Plus Panitumumab Patients With Metastatic KRAS Wild-Type Colorectal Cancer With Liver Metastases Only
A Phase II Study of FOLFOXIRI Plus Panitumumab Followed by Evaluation for Resection, in Patients With Metastatic KRAS Wild-Type Colorectal Cancer With Liver Metastases Only
Status: Enrolling
Updated: 7/1/2013
Providence Medical Group
mi
from
Terre Haute, IN
Click here to add this to my saved trials
FOLFOXIRI Plus Panitumumab Patients With Metastatic KRAS Wild-Type Colorectal Cancer With Liver Metastases Only
A Phase II Study of FOLFOXIRI Plus Panitumumab Followed by Evaluation for Resection, in Patients With Metastatic KRAS Wild-Type Colorectal Cancer With Liver Metastases Only
Status: Enrolling
Updated:  7/1/2013
Hope Cancer Center
mi
from
Terre Haute, IN
FOLFOXIRI Plus Panitumumab Patients With Metastatic KRAS Wild-Type Colorectal Cancer With Liver Metastases Only
A Phase II Study of FOLFOXIRI Plus Panitumumab Followed by Evaluation for Resection, in Patients With Metastatic KRAS Wild-Type Colorectal Cancer With Liver Metastases Only
Status: Enrolling
Updated: 7/1/2013
Hope Cancer Center
mi
from
Terre Haute, IN
Click here to add this to my saved trials
FOLFOXIRI Plus Panitumumab Patients With Metastatic KRAS Wild-Type Colorectal Cancer With Liver Metastases Only
A Phase II Study of FOLFOXIRI Plus Panitumumab Followed by Evaluation for Resection, in Patients With Metastatic KRAS Wild-Type Colorectal Cancer With Liver Metastases Only
Status: Enrolling
Updated:  7/1/2013
Center for Cancer & Blood Disorders
mi
from
Bethesda, MD
FOLFOXIRI Plus Panitumumab Patients With Metastatic KRAS Wild-Type Colorectal Cancer With Liver Metastases Only
A Phase II Study of FOLFOXIRI Plus Panitumumab Followed by Evaluation for Resection, in Patients With Metastatic KRAS Wild-Type Colorectal Cancer With Liver Metastases Only
Status: Enrolling
Updated: 7/1/2013
Center for Cancer & Blood Disorders
mi
from
Bethesda, MD
Click here to add this to my saved trials
FOLFOXIRI Plus Panitumumab Patients With Metastatic KRAS Wild-Type Colorectal Cancer With Liver Metastases Only
A Phase II Study of FOLFOXIRI Plus Panitumumab Followed by Evaluation for Resection, in Patients With Metastatic KRAS Wild-Type Colorectal Cancer With Liver Metastases Only
Status: Enrolling
Updated:  7/1/2013
Portsmouth Regional Hospital
mi
from
Portsmouth, NH
FOLFOXIRI Plus Panitumumab Patients With Metastatic KRAS Wild-Type Colorectal Cancer With Liver Metastases Only
A Phase II Study of FOLFOXIRI Plus Panitumumab Followed by Evaluation for Resection, in Patients With Metastatic KRAS Wild-Type Colorectal Cancer With Liver Metastases Only
Status: Enrolling
Updated: 7/1/2013
Portsmouth Regional Hospital
mi
from
Portsmouth, NH
Click here to add this to my saved trials
FOLFOXIRI Plus Panitumumab Patients With Metastatic KRAS Wild-Type Colorectal Cancer With Liver Metastases Only
A Phase II Study of FOLFOXIRI Plus Panitumumab Followed by Evaluation for Resection, in Patients With Metastatic KRAS Wild-Type Colorectal Cancer With Liver Metastases Only
Status: Enrolling
Updated:  7/1/2013
Hematology Oncology Associates of Northern NJ
mi
from
Morristown, NJ
FOLFOXIRI Plus Panitumumab Patients With Metastatic KRAS Wild-Type Colorectal Cancer With Liver Metastases Only
A Phase II Study of FOLFOXIRI Plus Panitumumab Followed by Evaluation for Resection, in Patients With Metastatic KRAS Wild-Type Colorectal Cancer With Liver Metastases Only
Status: Enrolling
Updated: 7/1/2013
Hematology Oncology Associates of Northern NJ
mi
from
Morristown, NJ
Click here to add this to my saved trials
FOLFOXIRI Plus Panitumumab Patients With Metastatic KRAS Wild-Type Colorectal Cancer With Liver Metastases Only
A Phase II Study of FOLFOXIRI Plus Panitumumab Followed by Evaluation for Resection, in Patients With Metastatic KRAS Wild-Type Colorectal Cancer With Liver Metastases Only
Status: Enrolling
Updated:  7/1/2013
Oncology Hematology Care
mi
from
Cincinnati, OH
FOLFOXIRI Plus Panitumumab Patients With Metastatic KRAS Wild-Type Colorectal Cancer With Liver Metastases Only
A Phase II Study of FOLFOXIRI Plus Panitumumab Followed by Evaluation for Resection, in Patients With Metastatic KRAS Wild-Type Colorectal Cancer With Liver Metastases Only
Status: Enrolling
Updated: 7/1/2013
Oncology Hematology Care
mi
from
Cincinnati, OH
Click here to add this to my saved trials
FOLFOXIRI Plus Panitumumab Patients With Metastatic KRAS Wild-Type Colorectal Cancer With Liver Metastases Only
A Phase II Study of FOLFOXIRI Plus Panitumumab Followed by Evaluation for Resection, in Patients With Metastatic KRAS Wild-Type Colorectal Cancer With Liver Metastases Only
Status: Enrolling
Updated:  7/1/2013
Chattanooga Oncology Hematology Associates
mi
from
Chattanooga, TN
FOLFOXIRI Plus Panitumumab Patients With Metastatic KRAS Wild-Type Colorectal Cancer With Liver Metastases Only
A Phase II Study of FOLFOXIRI Plus Panitumumab Followed by Evaluation for Resection, in Patients With Metastatic KRAS Wild-Type Colorectal Cancer With Liver Metastases Only
Status: Enrolling
Updated: 7/1/2013
Chattanooga Oncology Hematology Associates
mi
from
Chattanooga, TN
Click here to add this to my saved trials
FOLFOXIRI Plus Panitumumab Patients With Metastatic KRAS Wild-Type Colorectal Cancer With Liver Metastases Only
A Phase II Study of FOLFOXIRI Plus Panitumumab Followed by Evaluation for Resection, in Patients With Metastatic KRAS Wild-Type Colorectal Cancer With Liver Metastases Only
Status: Enrolling
Updated:  7/1/2013
The Family Cancer Center
mi
from
Collierville, TN
FOLFOXIRI Plus Panitumumab Patients With Metastatic KRAS Wild-Type Colorectal Cancer With Liver Metastases Only
A Phase II Study of FOLFOXIRI Plus Panitumumab Followed by Evaluation for Resection, in Patients With Metastatic KRAS Wild-Type Colorectal Cancer With Liver Metastases Only
Status: Enrolling
Updated: 7/1/2013
The Family Cancer Center
mi
from
Collierville, TN
Click here to add this to my saved trials
FOLFOXIRI Plus Panitumumab Patients With Metastatic KRAS Wild-Type Colorectal Cancer With Liver Metastases Only
A Phase II Study of FOLFOXIRI Plus Panitumumab Followed by Evaluation for Resection, in Patients With Metastatic KRAS Wild-Type Colorectal Cancer With Liver Metastases Only
Status: Enrolling
Updated:  7/1/2013
Tennessee Oncology, PLLC
mi
from
Nashville, TN
FOLFOXIRI Plus Panitumumab Patients With Metastatic KRAS Wild-Type Colorectal Cancer With Liver Metastases Only
A Phase II Study of FOLFOXIRI Plus Panitumumab Followed by Evaluation for Resection, in Patients With Metastatic KRAS Wild-Type Colorectal Cancer With Liver Metastases Only
Status: Enrolling
Updated: 7/1/2013
Tennessee Oncology, PLLC
mi
from
Nashville, TN
Click here to add this to my saved trials
FOLFOXIRI Plus Panitumumab Patients With Metastatic KRAS Wild-Type Colorectal Cancer With Liver Metastases Only
A Phase II Study of FOLFOXIRI Plus Panitumumab Followed by Evaluation for Resection, in Patients With Metastatic KRAS Wild-Type Colorectal Cancer With Liver Metastases Only
Status: Enrolling
Updated:  7/1/2013
The Center for Cancer and Blood Disorders
mi
from
Fort Worth, TX
FOLFOXIRI Plus Panitumumab Patients With Metastatic KRAS Wild-Type Colorectal Cancer With Liver Metastases Only
A Phase II Study of FOLFOXIRI Plus Panitumumab Followed by Evaluation for Resection, in Patients With Metastatic KRAS Wild-Type Colorectal Cancer With Liver Metastases Only
Status: Enrolling
Updated: 7/1/2013
The Center for Cancer and Blood Disorders
mi
from
Fort Worth, TX
Click here to add this to my saved trials
Dose Dense TC + Pegfilgrastim Support for Breast Cancer
Phase II Study of Dose-Dense TC (Docetaxel + Cyclophosphamide) With Pegfilgrastim Support for Adjuvant Therapy of pN0, pN1 or Nx Breast Cancer
Status: Enrolling
Updated:  7/2/2013
University of Wisconsin Carbone Cancer Center
mi
from
Madison, WI
Dose Dense TC + Pegfilgrastim Support for Breast Cancer
Phase II Study of Dose-Dense TC (Docetaxel + Cyclophosphamide) With Pegfilgrastim Support for Adjuvant Therapy of pN0, pN1 or Nx Breast Cancer
Status: Enrolling
Updated: 7/2/2013
University of Wisconsin Carbone Cancer Center
mi
from
Madison, WI
Click here to add this to my saved trials
18F-CP18 Imaging Studies for Cancer Treatment With Birinapant
A Pilot Study of [18F]-CP18 PET/CT Imaging in Patients With Relapsed Platinum Resistant or Refractory Epithelial Ovarian Cancer, Primary Peritoneal Cancer or Fallopian Tube Cancer Therapy Receiving Birinapant, a SMAC Mimetic Therapy
Status: Enrolling
Updated:  7/2/2013
National Institutes of Health Clinical Center
mi
from
Bethesda, MD
18F-CP18 Imaging Studies for Cancer Treatment With Birinapant
A Pilot Study of [18F]-CP18 PET/CT Imaging in Patients With Relapsed Platinum Resistant or Refractory Epithelial Ovarian Cancer, Primary Peritoneal Cancer or Fallopian Tube Cancer Therapy Receiving Birinapant, a SMAC Mimetic Therapy
Status: Enrolling
Updated: 7/2/2013
National Institutes of Health Clinical Center
mi
from
Bethesda, MD
Click here to add this to my saved trials
Loss of Grip Strength, BMI, and Adjuvant Endocrine Therapy Breast Cancer
A Prospective Assessment of Loss of Grip Strength by Baseline BMI in Breast Cancer Patients Receiving Adjuvant Third-generation Aromatase Inhibitors and Tamoxifen
Status: Enrolling
Updated:  7/5/2013
University of Michigan Comprehensive Cancer Center
mi
from
Ann Arbor, MI
Loss of Grip Strength, BMI, and Adjuvant Endocrine Therapy Breast Cancer
A Prospective Assessment of Loss of Grip Strength by Baseline BMI in Breast Cancer Patients Receiving Adjuvant Third-generation Aromatase Inhibitors and Tamoxifen
Status: Enrolling
Updated: 7/5/2013
University of Michigan Comprehensive Cancer Center
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
Evaluation of Clinical Safety of Combining Metformin With Anticancer Chemotherapy
Prospective Evaluation of Clinical Safety of Combining Metformin With Anticancer Chemotherapy
Status: Enrolling
Updated:  7/10/2013
Tufts Medical Center
mi
from
Boston, MA
Evaluation of Clinical Safety of Combining Metformin With Anticancer Chemotherapy
Prospective Evaluation of Clinical Safety of Combining Metformin With Anticancer Chemotherapy
Status: Enrolling
Updated: 7/10/2013
Tufts Medical Center
mi
from
Boston, MA
Click here to add this to my saved trials
Changes in Brain Structure Related to Systemic Chemotherapy Treatment: A Prospective Study in Individuals Diagnosed With Non-small Cell Lung Cancer Utilizing High-resolution Structural Magnetic Resonance Imaging
Changes in Brain Structure Related to Systemic Chemotherapy Treatment: A Prospective Study in Individuals Diagnosed With Non-small Cell Lung Cancer Utilizing High-resolution Structural Magnetic Resonance Imaging
Status: Enrolling
Updated:  7/11/2013
Memorial Sloan-Kettering Cancer Center
mi
from
New York, NY
Changes in Brain Structure Related to Systemic Chemotherapy Treatment: A Prospective Study in Individuals Diagnosed With Non-small Cell Lung Cancer Utilizing High-resolution Structural Magnetic Resonance Imaging
Changes in Brain Structure Related to Systemic Chemotherapy Treatment: A Prospective Study in Individuals Diagnosed With Non-small Cell Lung Cancer Utilizing High-resolution Structural Magnetic Resonance Imaging
Status: Enrolling
Updated: 7/11/2013
Memorial Sloan-Kettering Cancer Center
mi
from
New York, NY
Click here to add this to my saved trials
Relative Bioavailability Study of Enzalutamide in Prostate Cancer Patients
A Phase I, Open-label, Randomized, Parallel, Relative Bioavailability Study Comparing a Capsule and a Tablet Formulation of Enzalutamide Following Multiple Once Daily Doses of 160 mg Enzalutamide in Male Subjects With Prostate Cancer
Status: Enrolling
Updated:  7/15/2013
University of Colorado Anschutz Medical Campus
mi
from
Aurora, CO
Relative Bioavailability Study of Enzalutamide in Prostate Cancer Patients
A Phase I, Open-label, Randomized, Parallel, Relative Bioavailability Study Comparing a Capsule and a Tablet Formulation of Enzalutamide Following Multiple Once Daily Doses of 160 mg Enzalutamide in Male Subjects With Prostate Cancer
Status: Enrolling
Updated: 7/15/2013
University of Colorado Anschutz Medical Campus
mi
from
Aurora, CO
Click here to add this to my saved trials
Relative Bioavailability Study of Enzalutamide in Prostate Cancer Patients
A Phase I, Open-label, Randomized, Parallel, Relative Bioavailability Study Comparing a Capsule and a Tablet Formulation of Enzalutamide Following Multiple Once Daily Doses of 160 mg Enzalutamide in Male Subjects With Prostate Cancer
Status: Enrolling
Updated:  7/15/2013
University of Chicago Medical Center
mi
from
Chicago, IL
Relative Bioavailability Study of Enzalutamide in Prostate Cancer Patients
A Phase I, Open-label, Randomized, Parallel, Relative Bioavailability Study Comparing a Capsule and a Tablet Formulation of Enzalutamide Following Multiple Once Daily Doses of 160 mg Enzalutamide in Male Subjects With Prostate Cancer
Status: Enrolling
Updated: 7/15/2013
University of Chicago Medical Center
mi
from
Chicago, IL
Click here to add this to my saved trials
Relative Bioavailability Study of Enzalutamide in Prostate Cancer Patients
A Phase I, Open-label, Randomized, Parallel, Relative Bioavailability Study Comparing a Capsule and a Tablet Formulation of Enzalutamide Following Multiple Once Daily Doses of 160 mg Enzalutamide in Male Subjects With Prostate Cancer
Status: Enrolling
Updated:  7/15/2013
University of Pittsburgh Medical Center
mi
from
Pittsburgh, PA
Relative Bioavailability Study of Enzalutamide in Prostate Cancer Patients
A Phase I, Open-label, Randomized, Parallel, Relative Bioavailability Study Comparing a Capsule and a Tablet Formulation of Enzalutamide Following Multiple Once Daily Doses of 160 mg Enzalutamide in Male Subjects With Prostate Cancer
Status: Enrolling
Updated: 7/15/2013
University of Pittsburgh Medical Center
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
Relative Bioavailability Study of Enzalutamide in Prostate Cancer Patients
A Phase I, Open-label, Randomized, Parallel, Relative Bioavailability Study Comparing a Capsule and a Tablet Formulation of Enzalutamide Following Multiple Once Daily Doses of 160 mg Enzalutamide in Male Subjects With Prostate Cancer
Status: Enrolling
Updated:  7/15/2013
South Texas Accelerated Research Therapeutics
mi
from
San Antonio, TX
Relative Bioavailability Study of Enzalutamide in Prostate Cancer Patients
A Phase I, Open-label, Randomized, Parallel, Relative Bioavailability Study Comparing a Capsule and a Tablet Formulation of Enzalutamide Following Multiple Once Daily Doses of 160 mg Enzalutamide in Male Subjects With Prostate Cancer
Status: Enrolling
Updated: 7/15/2013
South Texas Accelerated Research Therapeutics
mi
from
San Antonio, TX
Click here to add this to my saved trials
Stereotactic Radiation and OX40 in Patients With Breast Cancer Metastatic to the Liver or Lung
Phase I/II Study of Stereotactic Body Radiation Therapy to Metastatic Lesions in the Liver or Lung in Combination With Monoclonal Antibody to OX40 in Patients With Progressive Metastatic Breast Cancer After Systemic Therapy.
Status: Enrolling
Updated:  7/16/2013
Providence Portland Medical Center
mi
from
Portland, OR
Stereotactic Radiation and OX40 in Patients With Breast Cancer Metastatic to the Liver or Lung
Phase I/II Study of Stereotactic Body Radiation Therapy to Metastatic Lesions in the Liver or Lung in Combination With Monoclonal Antibody to OX40 in Patients With Progressive Metastatic Breast Cancer After Systemic Therapy.
Status: Enrolling
Updated: 7/16/2013
Providence Portland Medical Center
mi
from
Portland, OR
Click here to add this to my saved trials
Sorafenib in Treating Patients With Locally Advanced or Metastatic Kidney Cancer
Correlation of Pathologic Findings After Neo-adjuvant Sorafenib With Results of Diffusion-Weighted Magnetic Resonance Imaging in Patients With Locally Advanced or Metastatic Clear Cell Renal Cell Carcinoma
Status: Enrolling
Updated:  7/17/2013
Robert H. Lurie Comprehensive Cancer Center at Northwestern University
mi
from
Chicago, IL
Sorafenib in Treating Patients With Locally Advanced or Metastatic Kidney Cancer
Correlation of Pathologic Findings After Neo-adjuvant Sorafenib With Results of Diffusion-Weighted Magnetic Resonance Imaging in Patients With Locally Advanced or Metastatic Clear Cell Renal Cell Carcinoma
Status: Enrolling
Updated: 7/17/2013
Robert H. Lurie Comprehensive Cancer Center at Northwestern University
mi
from
Chicago, IL
Click here to add this to my saved trials
Analysis of Percutaneous Ablations for Cancer Treatment
Prospective Analysis of Percutaneous Ablations for Cancer Treatment
Status: Enrolling
Updated:  7/18/2013
Emory University Hospital
mi
from
Atlanta, GA
Analysis of Percutaneous Ablations for Cancer Treatment
Prospective Analysis of Percutaneous Ablations for Cancer Treatment
Status: Enrolling
Updated: 7/18/2013
Emory University Hospital
mi
from
Atlanta, GA
Click here to add this to my saved trials
A Study to Look at the Electrical Activity of the Heart in Subjects With Solid Tumor Cancers, Before and After Receiving the Study Treatment, GSK1120212
A Phase I, Single-Sequence, Placebo-Controlled, Single-Blind Study to Evaluate the Effect of Repeat Oral Dosing of GSK1120212 on Cardiac Repolarization in Subjects With Solid Tumors
Status: Enrolling
Updated:  7/18/2013
GSK Investigational Site
mi
from
San Antonio, TX
A Study to Look at the Electrical Activity of the Heart in Subjects With Solid Tumor Cancers, Before and After Receiving the Study Treatment, GSK1120212
A Phase I, Single-Sequence, Placebo-Controlled, Single-Blind Study to Evaluate the Effect of Repeat Oral Dosing of GSK1120212 on Cardiac Repolarization in Subjects With Solid Tumors
Status: Enrolling
Updated: 7/18/2013
GSK Investigational Site
mi
from
San Antonio, TX
Click here to add this to my saved trials
A Study to Look at the Electrical Activity of the Heart in Subjects With Solid Tumor Cancers, Before and After Receiving the Study Treatment, GSK1120212
A Phase I, Single-Sequence, Placebo-Controlled, Single-Blind Study to Evaluate the Effect of Repeat Oral Dosing of GSK1120212 on Cardiac Repolarization in Subjects With Solid Tumors
Status: Enrolling
Updated:  7/18/2013
GSK Investigational Site
mi
from
Salt Lake City, UT
A Study to Look at the Electrical Activity of the Heart in Subjects With Solid Tumor Cancers, Before and After Receiving the Study Treatment, GSK1120212
A Phase I, Single-Sequence, Placebo-Controlled, Single-Blind Study to Evaluate the Effect of Repeat Oral Dosing of GSK1120212 on Cardiac Repolarization in Subjects With Solid Tumors
Status: Enrolling
Updated: 7/18/2013
GSK Investigational Site
mi
from
Salt Lake City, UT
Click here to add this to my saved trials
A Comparison of Air Insufflation, Water Immersion and Water Exchange Colonoscopy in Diagnostic Patients
A Randomized, Controlled Trial Comparing Air Insufflation, Water Immersion and Water Exchange During on Demand Sedation Colonoscopy in Diagnostic Patients
Status: Enrolling
Updated:  7/18/2013
Sepulveda Ambulatory Care Center, VA Greater Los Angeles Healthcare System
mi
from
Los Angeles, CA
A Comparison of Air Insufflation, Water Immersion and Water Exchange Colonoscopy in Diagnostic Patients
A Randomized, Controlled Trial Comparing Air Insufflation, Water Immersion and Water Exchange During on Demand Sedation Colonoscopy in Diagnostic Patients
Status: Enrolling
Updated: 7/18/2013
Sepulveda Ambulatory Care Center, VA Greater Los Angeles Healthcare System
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Dose Escalation Study of MLN0128 in Combination With Paclitaxel, With/Without Trastuzumab, in Subjects With Advanced Solid Malignancies
A Phase I, Open Label, Dose Escalation Study of Oral Administration of MLN0128 in Combination With Paclitaxel, With/Without Trastuzumab, in Subjects With Advanced Solid Malignancies
Status: Enrolling
Updated:  7/23/2013
Clinical Research Facility
mi
from
Daytona Beach, FL
Dose Escalation Study of MLN0128 in Combination With Paclitaxel, With/Without Trastuzumab, in Subjects With Advanced Solid Malignancies
A Phase I, Open Label, Dose Escalation Study of Oral Administration of MLN0128 in Combination With Paclitaxel, With/Without Trastuzumab, in Subjects With Advanced Solid Malignancies
Status: Enrolling
Updated: 7/23/2013
Clinical Research Facility
mi
from
Daytona Beach, FL
Click here to add this to my saved trials
Dose Escalation Study of MLN0128 in Combination With Paclitaxel, With/Without Trastuzumab, in Subjects With Advanced Solid Malignancies
A Phase I, Open Label, Dose Escalation Study of Oral Administration of MLN0128 in Combination With Paclitaxel, With/Without Trastuzumab, in Subjects With Advanced Solid Malignancies
Status: Enrolling
Updated:  7/23/2013
Clinical Research Facility
mi
from
Tulsa, OK
Dose Escalation Study of MLN0128 in Combination With Paclitaxel, With/Without Trastuzumab, in Subjects With Advanced Solid Malignancies
A Phase I, Open Label, Dose Escalation Study of Oral Administration of MLN0128 in Combination With Paclitaxel, With/Without Trastuzumab, in Subjects With Advanced Solid Malignancies
Status: Enrolling
Updated: 7/23/2013
Clinical Research Facility
mi
from
Tulsa, OK
Click here to add this to my saved trials
Dose Escalation Study of MLN0128 in Combination With Paclitaxel, With/Without Trastuzumab, in Subjects With Advanced Solid Malignancies
A Phase I, Open Label, Dose Escalation Study of Oral Administration of MLN0128 in Combination With Paclitaxel, With/Without Trastuzumab, in Subjects With Advanced Solid Malignancies
Status: Enrolling
Updated:  7/23/2013
Clinical Research Facility
mi
from
Chattanooga, TN
Dose Escalation Study of MLN0128 in Combination With Paclitaxel, With/Without Trastuzumab, in Subjects With Advanced Solid Malignancies
A Phase I, Open Label, Dose Escalation Study of Oral Administration of MLN0128 in Combination With Paclitaxel, With/Without Trastuzumab, in Subjects With Advanced Solid Malignancies
Status: Enrolling
Updated: 7/23/2013
Clinical Research Facility
mi
from
Chattanooga, TN
Click here to add this to my saved trials
A Study of Investigational SAR256212 in Combination With SAR245408 in Patients With Solid Tumor Cancers
A Phase 1b Dose-escalation Study of the Safety and Pharmacokinetics of SAR245408 Administered in Combination With SAR256212 in Patients With Solid Tumor Cancers
Status: Enrolling
Updated:  7/29/2013
Clinical Research Facility
mi
from
Boston, MA
A Study of Investigational SAR256212 in Combination With SAR245408 in Patients With Solid Tumor Cancers
A Phase 1b Dose-escalation Study of the Safety and Pharmacokinetics of SAR245408 Administered in Combination With SAR256212 in Patients With Solid Tumor Cancers
Status: Enrolling
Updated: 7/29/2013
Clinical Research Facility
mi
from
Boston, MA
Click here to add this to my saved trials
A Study of Investigational SAR256212 in Combination With SAR245408 in Patients With Solid Tumor Cancers
A Phase 1b Dose-escalation Study of the Safety and Pharmacokinetics of SAR245408 Administered in Combination With SAR256212 in Patients With Solid Tumor Cancers
Status: Enrolling
Updated:  7/29/2013
Clinical Research Facility
mi
from
Boston, MA
A Study of Investigational SAR256212 in Combination With SAR245408 in Patients With Solid Tumor Cancers
A Phase 1b Dose-escalation Study of the Safety and Pharmacokinetics of SAR245408 Administered in Combination With SAR256212 in Patients With Solid Tumor Cancers
Status: Enrolling
Updated: 7/29/2013
Clinical Research Facility
mi
from
Boston, MA
Click here to add this to my saved trials
A Study of Investigational SAR256212 in Combination With SAR245408 in Patients With Solid Tumor Cancers
A Phase 1b Dose-escalation Study of the Safety and Pharmacokinetics of SAR245408 Administered in Combination With SAR256212 in Patients With Solid Tumor Cancers
Status: Enrolling
Updated:  7/29/2013
Clinical Research Facility
mi
from
Knoxville, TN
A Study of Investigational SAR256212 in Combination With SAR245408 in Patients With Solid Tumor Cancers
A Phase 1b Dose-escalation Study of the Safety and Pharmacokinetics of SAR245408 Administered in Combination With SAR256212 in Patients With Solid Tumor Cancers
Status: Enrolling
Updated: 7/29/2013
Clinical Research Facility
mi
from
Knoxville, TN
Click here to add this to my saved trials
Mindfulness-Based Stress Reduction (MBSR) Symptom Cluster Trial for Breast Cancer Survivors
Mindfulness-Based Stress Reduction (MBSR) Symptom Cluster Trial for Breast Cancer Survivors
Status: Enrolling
Updated:  7/30/2013
University of South Florida
mi
from
Tampa, FL
Mindfulness-Based Stress Reduction (MBSR) Symptom Cluster Trial for Breast Cancer Survivors
Mindfulness-Based Stress Reduction (MBSR) Symptom Cluster Trial for Breast Cancer Survivors
Status: Enrolling
Updated: 7/30/2013
University of South Florida
mi
from
Tampa, FL
Click here to add this to my saved trials
Mindfulness-Based Stress Reduction (MBSR) Symptom Cluster Trial for Breast Cancer Survivors
Mindfulness-Based Stress Reduction (MBSR) Symptom Cluster Trial for Breast Cancer Survivors
Status: Enrolling
Updated:  7/30/2013
Moffitt Cancer Center and Research Institute
mi
from
Tampa, FL
Mindfulness-Based Stress Reduction (MBSR) Symptom Cluster Trial for Breast Cancer Survivors
Mindfulness-Based Stress Reduction (MBSR) Symptom Cluster Trial for Breast Cancer Survivors
Status: Enrolling
Updated: 7/30/2013
Moffitt Cancer Center and Research Institute
mi
from
Tampa, FL
Click here to add this to my saved trials